4DMedical

4DMedical FCF/Debt

The Free Cash Flow to Debt Ratio of 4DMedical (4DX.AX) as of Nov 11, 2026 is -1,001.78 %. In the previous year, Free Cash Flow to Debt Ratio was -802.25 % — a change of 24.87% (lower).

FCF/Debt

-1,001.78 %

YoY

24.87%

Last updated:

Free Cash Flow to Debt Ratio of 4DMedical is 2026 -1,001.78 % . Free Cash Flow to Debt Ratio of 4DMedical was 2025 -802.25 % . It decreases by 24.87% lower compared to the previous year.

The 4DMedical FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-235.43 AUD
Jan 1, 2020
-52.22 AUD
Jan 1, 2021
-902.71 AUD
Jan 1, 2022
-454.35 AUD
Jan 1, 2023
-455.05 AUD
Jan 1, 2024
-608.71 AUD
Jan 1, 2025
-802.25 AUD
Jan 1, 2026
-1,001.78 AUD
The 4DMedical FCF/Debt history
YEARFCF/DebtYoY
-1,001.78 %+24.87%
-802.25 %+31.79%
-608.71 %+33.77%
-455.05 %+0.16%
-454.35 %-49.67%
-902.71 %+1,628.77%
-52.22 %-77.82%
-235.43 %-51.03%
-480.75 %-100.00%
-328.74 M %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

4DMedical Stock analysis

What does 4DMedical do? 4DMedical Ltd. commercializes its XV Technology, a four-dimensional lung imaging platform, through FDA-cleared XV Lung Ventilation Analysis Software (XV LVA) and CT LVAS, delivered via a software-as-a-service model. The company sells these products to hospitals and clinics, including I-MED Radiology Network, which operates approximately 250 clinics nationwide. XV LVAS and CT LVAS reports are generated using the company’s software, leveraging existing hospital imaging equipment or the XV Scanner. The firm’s revenue comes from SaaS subscriptions and software licensing for its imaging solutions. I-MED Radiology Network is a key client, with 4DMedical initiating the commercial rollout of XV LVAS within its network. The company provides lung imaging technology to selected clinics across I-MED, utilizing the XV Scanner or existing hospital equipment. Revenue streams are derived from the SaaS delivery model, with no mention of additional products or services beyond XV LVA and CT LVAS. 4DMedical’s flagship technology powers dynamic lung ventilation analysis, enabling physicians to identify respiratory issues earlier. The company’s products are designed for use with existing hospital imaging systems, reducing the need for additional hardware. The primary buyers are medical imaging providers like I-MED, which integrate XV Technology into their diagnostic services for respiratory conditions. 4DMedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 4DMedical stock

Free Cash Flow to Debt Ratio of 4DMedical is -1,001.78 % in 2026.

Free Cash Flow to Debt Ratio of 4DMedical changed from -802.25 % to -1,001.78 %, representing a 24.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio 4DMedical since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's 4DMedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — 4DMedical

All Key Metrics — 4DMedical